---
title: "Moderna Secures FDA Approval for mFlusiva as First mRNA Influenza Vaccine"
url: https://projectchintan.com/article/fda-approves-moderna-mflusiva-first-mrna-flu-vaccine-kzl12
publisher: Project Chintan
author: Project Chintan Newsroom
section: Technology
published: 2026-08-06T06:45:26.000Z
modified: 2026-08-06T09:00:52.321Z
language: en-IN
---

# Moderna Secures FDA Approval for mFlusiva as First mRNA Influenza Vaccine

The U.S. Food and Drug Administration has authorized the first messenger RNA-based seasonal flu shot for adults aged 50 and older. Clinical trials involving 40,000 participants demonstrated that mFlusiva outperformed standard-dose vaccines by 26.6 percent.

## Key takeaways

- Moderna received FDA approval for mFlusiva, the first mRNA-based seasonal influenza vaccine for adults 50 and older.
- Clinical trials showed the mRNA shot was 26.6% more effective than standard-dose vaccines in the targeted age group.
- Revenue from mFlusiva is expected to start in late 2027 after Moderna missed the 2026 contracting cycle.
- The approval follows leadership changes at the FDA, including the resignations of Marty Makary and Vinay Prasad.

## Federal Authorization Details

On August 5, 2026, Moderna announced the FDA approval of mFlusiva, a seasonal influenza vaccine tailored for the aging population. The regulatory agency granted traditional approval for adults between 50 and 64 years old. For individuals 65 and older, the shot received accelerated approval, contingent on Moderna conducting further studies to verify clinical benefits in this senior demographic.

## Comparative Efficacy and Technology

Data from a late-stage clinical trial with over 40,000 subjects formed the basis of the FDA's decision. Results indicated that mFlusiva was 26.6% more effective than existing licensed standard-dose influenza vaccines. Furthermore, Moderna provided secondary late-stage data showing that its product elicited more robust antibody responses in seniors compared to Sanofi's high-dose alternative.

Unlike traditional vaccines that rely on egg-based production and viral proteins, mFlusiva utilizes mRNA technology. This method instructs the body to manufacture influenza antigens, potentially allowing manufacturers to update vaccine strains more rapidly to match circulating viruses.

## Market Outlook and Institutional Shifts

Financial analysts anticipate that mFlusiva will not contribute significantly to revenue until the latter half of 2027. This delay stems from Moderna missing the contracting window for the 2026 U.S. flu season. Jefferies analysts project combined U.S. sales for this flu shot and a future COVID-flu combination vaccine to reach $750 million by 2030.

The approval follows a period of transition within the FDA. Former Commissioner Marty Makary and vaccine chief Vinay Prasad resigned earlier in the year following disputes over the review processes for rare-disease drugs and vaccines. Acting Commissioner Kyle Diamantas is currently overseeing the agency's efforts to stabilize operations and restore trust within the pharmaceutical sector.

## Key Facts

- The vaccine is approved for two distinct tiers: traditional approval for ages 50-64 and accelerated for ages 65+.
- Trial data shows a 26.6% increase in efficacy over standard-dose vaccines.
- Moderna aims to offset declining COVID-19 vaccine revenue through this new mRNA product line.
- Competition in the market includes established shots from Sanofi, GSK, CSL Seqirus, and AstraZeneca.

Source: The Hindu — Sci-Tech

---
Canonical: https://projectchintan.com/article/fda-approves-moderna-mflusiva-first-mrna-flu-vaccine-kzl12
Reported from: The Hindu — Sci-Tech